A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients With Refractory Leukemia  by Gergis, U. et al.
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database and survey sheets.
Results: Four hundred fifty patients (255 males and 195 females)
with a median age of 44-year-old (range 15-68) were included in
this study. All patients had underlying hematological malignancies
except 13 patients with aplastic anemia. Median serum creatinine
level before conditioning was 0.64 (0.32 - 1.33) mg/dl. After correct-
ing the Ccr data by actual body surface area in patients whose body
heights and body weights were available, corrected Ccr was 107 (34 -
372) ml/min/1.73m2. Patients with mildly reduced renal function (\
90 ml/min/1.73 m2) were further classified into group 1 (23 patients,
5.6%) and group 2 (97 patients, 23.7%), according to the corrected
Ccr of 30-59 and 60-89 ml/min/1.73 m2, respectively. Twenty-four
patients (19 patients within 100 days and 5 patients after 100 days)
developed severe renal failure which required hemodialysis after
HSCT. Hemodialysis was discontinued in 5 patients upon recovery
of renal function. Probability of requiring hemodialysis was 13% in
the group 1, which was higher than that in the group 2 (2.1%) and
that in the normal renal function group (6.6%), but the difference
was not statistically significant. The incidences of NRM within 30
days or 100 days after HSCT and grade II to IV acute graft-ver-
sus-host disease did not differ among these three groups.
Conclusion: Similarly to the results of HCT-CI analysis, mildly
reduced renal function before allogeneic HSCT did not affect the
outcome of HSCT.Table 1. Patient, Disease, and Transplantation Characteristics
Characteristic Evaluable-10
Age
Mean 57.5
Range 42-71
Male sex 2
Disease
AML 8
ALL 2
Time between diagnosis and SCT
Mean 446.4
Range 161-1683
Donor
MRD 4
MUD 6
Cohort 1A 6
Cohort 2A 3
Cohort 1B 1
Cycles of chemotherapy prior to SCT
Mean 4
Range 2-9
Bone marrow blasts at starting CPX
Mean 50
Range 8-83
Circulating blasts at starting CPX
Mean 33.4
Range 0-49
CD 34 cell dose infused  10^6/kg
Mean 5.9
Range 3.59-10.17416
THE STEMEX PHASE II/III STUDY: CHALLENGES IN PRODUCTION AND
DELIVERY OF CENTRALLY MANUFACTURED EX VIVO EXPANDED
UMBILICAL CORD BLOOD (UCB) CD133+ CELLS TO PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Snyder, D., Landau, E., Rosenheimer, N.G., Mandel, J., Glukhman, E.,
Hasson, N., Lador, C., Olesinski, E., Hagler-Price, G., Leshem, A.,
Freind, E., Ben Abu, K., Sharabi, S., Shachaf, O., Israeli, H.,
Harati, D., Srur-Kidron, O., Bracha, D., Peled, T. Gamida Cell Ltd.,
Jerusalem, Israel
Use of UCB as an alternative SC source is limited due to inade-
quate TNC&CD34+ cells, in that it is often difficult to find a single
unit for successful engraftment in adolescents & adults. One strategy
to overcome this limitation is to increase the number of cells by ex-
pansion of HPC. StemExwas developed as a cell graft based on use
of a copper chelator (TEPA) that delays differentiation & promotes
expansion of HPC with engraftment capabilities. StemEx is manu-
factured from a fraction of a single CBU originally frozen in 2 sep-
arate fractions. CD133+ progenitor cells purified from the smaller
or equal fraction are cultured for 21 days with cytokines & TEPA.
The product is transplanted to the patient 24h after infusion of the
unmanipulated fraction. A global pivotal Phase II/III registration
study is underway to evaluate the safety & efficacy of StemEx in
patients with advanced hematological malignancies.
Taking into consideration the variability in the intrinsic potential
& the cryopreservation processes of the CBUs, successful & robust
manufacturing of clinical batches is one of the major challenges of
this study. 61 StemEx batches have been manufactured so far in 3
centralized GMP facilities in US, EU & Israel. All the fresh hand-
carried batches were successfully delivered to the centers within
the StemEx stability period. Of the 61 batches, 58 successfully passed
the in-process & final process quality control (IPQC & FPQC) cri-
teria: median fold expansion of TNC, CD34+ cells & CFU over cul-
ture input values were 377 (52-743, n 5 58), 74 (6-206, n 5 57) &
111 (43-662, n 5 56), respectively. Expansion of only a portion of
the CBU resulted in a median 9.6 fold increase (0.8-90.3 n 5 58)
in the total number of CD34+ cells infused, over the theoretical num-
ber of CD34+ cells that would be infused from the entire CBU with-
out expansion. Interestingly, all three batches that failed to expand
also did not pass the IPQC criteria:$ 10 CFU/1000 freshly purified
CD133+ cells at day 0 of production. This information, available be-
fore initiation of patient myeloablation, provides further confidence
regarding the quality of the CBU & the StemEx product.
With the significant production challenges of an ex vivo expanded
product being successfully met in the current registration trial, Ste-
mEx study demonstrates the feasibility of this approach in satisfying
an urgent unmet clinical need in the UCB transplantation setting.417
A NOVEL SEQUENTIAL TREATMENT UTILIZING CPX-351 AS SALVAGE
CHEMOTHERAPY FOLLOWED BY A REDUCED INTENSITY CONDITIONING
ALLOGENEIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH
REFRACTORY LEUKEMIA
Gergis, U., Ritchie, E., Roboz, G.J., Scandura, J.M., Mayer, S.,
Mark, T.M., Shore, T.B., Wissa, U., Feldman, E.J. Weill Cornell
Medical College, New York, NY
Cytoreduction followed by Reduced Intensity Conditioning
(RIC) may lead to improved results in allogeneic stem cell transplant
(SCT) for refractory leukemia. CPX-351 is a novel liposomal formu-
lation that encapsulates the combination of cytarabine and daunoru-
bicin in a fixed 5: 1 ratio. In vitro, it selectively concentrates in the
marrow. Clinically, CPX-351 is well tolerated, with a favorable tox-
icity profile. In a phase I trial, patients with refractory acute leukemia
were treated with escalating doses of CPX-351 starting at 60 mg/m2
on days - 28, -26 and -24 followed by RIC with IV busulfan 3.2 mg/
kg/day on days -6 to -3 and fludarabine 30 mg /m2/day on days -6 to
-3 (Bu/Flu). GVHD prophylaxis with tacrolimus and methotrexate.
The protocol was amended to include a second arm, B to shorten the
duration prior to stem cell infusion to 3 weeks. Fifteen patients
(AML-12, ALL-2, CML in blast crisis-1) have been enrolled to
date. Five patients are inevaluable due to short follow up (2), sepsis
resulting in aborted transplant plans (2) and donor’s unavailability
(1). Ten patients underwent SCT are evaluable (AML-8, ALL-2).
All patients received HLA compatible grafts (MUD-8, MRD-2).
Three patients had primary induction failure and 7 had relapsed re-
fractory disease. All evaluable patients achieved adequate neutrophil
engraftment at a mean of 16.6 days (range 12-35). Nine patients
achieved adequate platelet engraftment at a mean of 15.8 days (range
11-33). Eight patients achieved complete hematologic and cytoge-
netic remission upon full blood counts recovery. One patient had
full neutrophil and platelets engraftment but did not have a bone
marrow biopsy as of this date. Two patients (ALL) had a disease re-
lapse 24 and 60 days post transplant. Acute GVHDoccurred in 3 pa-
tients. One patient with a stage 2 skin GVHD and 2 patients had
stage 3-4 GI GVHD upon cessation of immunosupression 5 and 9
months post transplantation. Grade 3 mucositis developed in 4 pa-
tients.The 100 days overall survival and disease free survival for 8
evaluable patients was 85% and 78% respectively. At a mean follow
S306 Poster Session IIup time of 6.5 months, one patient died of disease relapse (ALL),
Two patients died of acute GVHD and 7 patients are alive without
evidence of leukemia. CPX-351 followed by RIC SCT is feasible,
and further dose escalation and schedule adjustment to define
MTD is ongoing. Remission status is not a prerequisite for a success-
ful outcome in selected patients.418
HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES
OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-
BASED REDUCED TOXICITY CONDITIONING (RTC)
Hamadani, M.1, Craig, M.1, Abraham, J.1, Tse, W.1, Cumpston, A.1,
Gibson, L.F.1, Remick, S.C.1, Leadmon, S.1, Elder, P.2, Hofmeister, C.2,
Penza, S.2, Andritsos, L.2, Blum, W.2, Benson DM Jr.2, Devine, S.M.2
1West Virginia University, Morgantown, WV; 2The Ohio State
University, Columbus, OH
We evaluated the impact of busulfan dose-intensity in patients un-
dergoing RTC AHCT in a multicenter retrospective study of 112
consecutive patients. Seventy-five patients were conditioned with
busulfan (0.8 mg/kg/dose IV x 8 doses [6.4mg/kg total dose]), fludar-
abine (30mg/m2/day, days -7 to -3), and 6mg/kg of ATG (L-FBA
group), while 37 patients received a more-intense RTC with busul-
fan (130mg/m2/day IV, days -6 to -3 [12.8mg/kg total dose]), fludar-
abine (40mg/m2/day, days -6 to -3), and 6mg/kg of ATG (H-FBA
group). At baseline (see Table 1.) the L-FBA and H-FBA groups
were matched for median age (58yr vs. 55yr; p5 0.3), unrelated do-
nor allografts (88% vs. 75%; p 5 0.1), and HLA-mismatched allo-
grafts (22% vs. 21%; p 5 0.9). More patients in L-FBA group had
high-risk disease (88% vs. 75%; p 5 0.01), higher median HCT-
CI (2 vs. 1; p 5 0.01) and better KPS (90 vs. 80; p 5 0.001).
Table 1. Baseline Characteristics of Patients Undergoing RTC
with FBA
L-FBA [N575] H-FAB [N537] p-ValueAge (median) 58 years 55 years 0.3
Unrelated Donors 66 (88%) 28 (75%) 0.1
High-risk Disease* 66 (88%) 25 (67%) 0.01
Diagnosis
AML/ALL 28% 43% 0.1
MDS 12% 21% 0.18
NHL/Hogkin’s Lymphoma 24% 21% 0.77
CLL/CML 34% 8% 0.002
Others 1.3% 5.4% 0.2
KPS (median) 90 80 0.001
HCT-CI (median) 2 1 0.01
HLA-mismatched transplants 17 (22%) 8 (21%) 0.9
Follow-up (surviving pts;
median)404 days 378 days 0.2*High-risk per standard CIBMTR criteria. HCT-CI, Hematopoietic cell
transplantation comorbidity index; KPS, Karnofsky performance score.
GVHD prophylaxis consisted of micro-dose methotrexate/ calci-
neurin inhibitor combination. There were no graft rejections. Me-
dian time to neutrophil (16days vs. 17days; p 5 0.03) and platelet
engraftment (14days vs. 16days; p 5 0.0001) was significantly faster
in H-FBA group. Compared to patients receiving H-FBA, those re-
ceiving L-FBA had fewer bacterial infections (56% vs. 32%; p-value
5 0.01), similar CMV reactivations (p5 0.6) and more EBV reacti-
vations (0% vs. 16%; p 5 0.001). For L-FBA and H-FBA groups
rates of grade II-IV acute GVHD (41% vs. 47%; p-value 5 0.68),
and chronic GVHD (35% vs. 46%; p-value5 0.21) were not signif-
icantly different. In similar order at 1-year the cumulative-incidence
of non-relapse mortality (NRM) (11% vs. 22%; p-value 5 0.2) and
relapse rates (37% vs. 40%; p5 0.8) were not significantly different.
The median follow-up of surviving patients is 14 months. Patients in
L-FBA and H-FBA groups had similar 1-year overall survival (61%
vs. 50% p5 0.1) and progression free survival (51% vs. 36% p-value
5 0.3). Our data suggest that merits of higher busulfan dose-inten-
sity in the context of FBA-based RTC may be offset by slightlyincreased early morbidity and NRM, suggesting prospective trials
are warranted.
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THE NUMBER OF CD34+ CELLS IN PERIPHERAL BLOOD PRE LEUKAPHE-
RESIS OF ALLOGENEIC STEM CELL DONORS IS RELATED TO DONOR
DEMOGRAPHIC AND HEMATOLOGIC FACTORS ON THE DAY OF COLLEC-
TION. RESULTS OF A SINGLE CENTER STEM CELL COLLECTION
VALIDATION STUDY
Baron, C., Ahmad, I., Busque, L., Cohen, S., Depeault, L., Lachance, S.,
Roy, D.C., Roy, J., Sauvageau, G., Kiss, T.L. Maisonneuve Rosemont
Hospital, University of Montreal, Montreal, QC, Canada
Introduction: Leukapheresis has become the preferred tool of stem
cell collection for allogeneic transplants. CD34 cell count per ml in
peripheral blood on the day of collection can be used to estimate col-
lection yield. CD34 counts show variability related to donor specific
factors. We have identified in this study predictive factors influenc-
ing CD34 cell count and collection yield in a homogenous cohort of
donors.
Methods: 269 collections were performed in 217 consecutive alloge-
neic stem cell transplant donors in the pheresis unit of Maisonneuve
Rosemont Hospital between 2006 and 2009. Median age was 50
years (22-76). 99 (46%) were female. G-CSF was used at a dose of
5mg/kg BID for 4 days. Collections were initiated at a level of 10
CD34 cells/ml on day 5 using a Cobe Spectra pheresis device.
Results:Median blood volume cycled was 15.9 liters (5-20). 174 do-
nors (80%) required one collection to achieve a graft of 5x106/kg, 43
required additional collections. Median CD34 count/ml was 71 (4.5-
378.5). Male had a higher CD34 count/ml on all days of collection as
female donors (95 versus 73 CD34/ml, p5 0.001). Women and men
above the age of 55 had lower CD34 counts/ml as compared to youn-
ger donors (women: 94 versus 74, p5 0.022; men: 113 versus 83, p5
0.013). More female than male donors required multiple collections
to achieve a satisfactory graft (27 versus 14%, p\0.01). There were
statistically significant positive correlations between total leucocyte
(lc), mononuclear cell (MNC), platelet (plt) and CD34 counts/ml
measured in the peripheral blood. No correlation between hemoglo-
bin and CD34 count was noted. A median of 4.8x108 CD34 + cells
were collected per graft (0.2-19.5). A significant positive correlation
was noted between collection yield and pre collection total lc, MNC,
plt, CD34 /ml and total lc count in the graft. The median collection
efficiency (CE) for the whole cohort was 42%.We observed a signif-
icantly higher CE using a manual mode of collection as compared to
an automatic mode (46 vs 29%, p\ 0.001).
Conclusions: CD34 cell count pre collection is affected by donor
age and gender. A higher proportion of female donors require mul-
tiple collections. A number of haematological parameters are corre-
lated with an elevated CD34 count in peripheral blood on the day of
collection.These factors help determine donors at higher risk of a de-
creased yield of stem cell collection. A manual mode of collection
appears to lead to superior collection efficiency.420
THE ROLE OF AMD3100 AS A PREPARATIVE REGIMEN IN ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Ko, R.M., Logronio, K., Czechowicz, A., Shizuru, J.A. Stanford Univer-
sity, Palo Alto, CA
Since the development of allogeneic hematopoietic cell transplan-
tation (HCT),many advances have beenmade that allowHCT treat-
ment to be utilized in a wider range of patients. In the face of all these
developments, additional barriers to engraftment have emerged. In
addition to the immune barrier, non-immune related barriers are
thought to contribute to engraftment resistance. One physical bar-
rier of HCT engraftment is a need for space in the host hematopoi-
etic stem cell (HSC) niche. It has been suggested that donor cells
must home to specific areas in the bone marrow, engraft, and prolif-
erate in these spaces. If endogenous HSCs occupy the niche, it is hy-
pothesized that incoming donor cells will not be able to engraft.
AMD3100 is a small molecule antagonist of CXC chemokine re-
ceptor 4 (CXCR4) and functions to block CXCR4 and stromal
cell-derived factor-1 (SDF-1) interactions. This blockade results in
